Clinical Trial Update: PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PD-1 inhibitor plus anlotinib with multimodal radiotherapy for recurrent or metastatic anaplastic thyroid cancer (experiment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• PD-1 inhibitor

Snippet

Sponsor: West China Hospital | Conditions: Thyroid Cancer | Phase 2 | Status: UNKNOWN